Cytotoxic chemotherapy for advanced or recurrent cervical cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Green, J A ^a   Lainakis, G ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLACINOMYCIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LEUKOPENIA; MONOTHERAPY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 33749600031     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl265     Document Type: Article

References (32)

1. Ferlay J, Bray F, Piscini P et al. GLOBOCON 2000. Cancer incidence, mortality and prevalence worldwide 1.0 edn. IARC 2001; 5.
2. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 127-128.
3. Alfsen GC, Kristensen GB, Skovlund E et al. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix; a population-based study of prognostic factors in 505 patents with non-squamous cell carcinomas of the cervix. Cancer 2001; 92: 2471-2483.
4. Green JA, De Barros Lopes A. Optimizing treatment for cervical cancer. The value of chemoradiation. Am J Cancer 2004; 3: 215-227.
5. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer: A systematic review and meta-analysis of individual patent data from 21 randomized controlled trials. Eur J Cancer 2003; 39: 2470-2486.
6. Bloss JD, Thigpen JT. Chemotherapy of gynaecological cancers. In Perry MC (ed.): The Chemotherapy Source Book, 3rd edition. Philadelphia, Lippincott 2001; 732.
7. Verschrogen CF, Leung T, Kudelka AP et al. Phase II study of irinotecan in prior chemotherapy treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625.
8. Kudelka AP, Wirin R, Edwards CL et al. Activity of paclitaxel in advanced or recurrent squamous cell carcinoma of the cervix: A Gynaecologic Oncology Group study. Clin Cancer Res 1996; 2: 1285-1288.
9. Kaem J, Trope C, Kjorstad KE et al. A phase II study of 5-fluorouracil/ cisplatin in recurrent cervical cancer. Tidsskr Nor Laegeforen 1990; 110: 2759-2762.
10. Jenkins AD, Ramondetta LM, Sun C et al. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Onool 2005; 97: 840-844.
11. Buxton EJ, Meanwell CA, Hilton C, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989; 81: 359-361.
12. Brader KR, Morris M, Levenback C et al. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design. J Clin Oncol 1998; 16: 1879-1884.
13. Murad AM, Triginelli SA, Ribalta JCL. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994; 12: 55-59.
14. Pignata S, Silvestro G, Ferrani E et al. A phase II study of cisplatin and vinorelbine as first line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol 1999; 17: 756-760.
15. Burnett AF, Roman LD Garcia AA et al. A phase II study of gemcitabine and cisplatin in patients with advanced persistent or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000; 76: 63-66.
16. Moore DH, McQuellon RP, Blessing JA et al. Phase III study of cisplatin with or without paclitaxel in stage IVB recurrent or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 3113-3119.
17. Omura GA, Blessing JA, Vaccarello L et al. Randomised trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix. J Clin Oncol 1997; 15; 165-171.
18. Dimopoulos MA, Papadimitriou CA, Sarris K et al. Combination of ifosfamide, paclitaxel and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: A phase II study of the Hellenic Cooperative Oncology Group Gynecol Onool 2002; 85: 476-482.
19. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in non-squamous carcinomas of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 1275-1278.
20. Long HJ, III, Bundy BN, Grendys EC Jr. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-4633.
21. Buda A, Fossati R, Colombo N et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifostamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005; 23: 4137-4145.
22. Ohwada M, Macliada H, Fujiano R et al. Phase I and II studies of combination chemotherapy using irinotecan and neplatin for advanced or recurrent cervical cancer. Proc ASCO 2003; 22: 478.
23. Porras A, Quistiani F, Gallasto R et al. Gemcitabine plus irinotecan in recurrent cervical cancer: A pilot study. Proceedings ASCO 2004; 22: 5118.
24. Bonzil K, Maffouf H. A phase II study of gemcitabine and cisplatin combination in the treatment of recurrent cervical squamous cell carcinoma. Proc ASCO 2003; 22: 473.
25. Nagro S, Fujiova K, Oda H et al. Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus: A pilot study. Proc ASCO 2004; 22: 5019.
26. Townsley CA, Elit L, Carey M et al. A multicentre phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patents with unresected locally advanced metastatic cervical carcinoma. Proceedings ASCO 2005; 24: 5103.
27. Muggia FM, Blessing JA, Waggoner S et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 2005; 96: 108-111.
28. Takehara M. Experimental and clinical study on chemotherapy for cervical adenocarcinoma. Sopporo Med J 1996; 65: 433-444.
29. Tsutomu T, Keisuke N, Kenji Y et al. A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix, Int J Clin Oncol 2004; 1: 59-63.
30. Onishi Y, Yamamoto F, Nakamura T, Hatae M. First-line treatment of cervical adenocarcinoma with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2005; 24: 5146.
31. Monk BJ, Huang HQ, Cella D, Long HJ III. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynaecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617-4625.
32. Vorsteher N, Bühler H, Duvnjak B et al. Expression patterns and prognostic significance of human epidermal growth factor receptors (HER family) in squamous cell carcinoma of the cervix. J Clin Oncol 2004: 22 (14S): 5030.